Back to Search Start Over

Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target.

Authors :
Asim M
Massie CE
Orafidiya F
Pértega-Gomes N
Warren AY
Esmaeili M
Selth LA
Zecchini HI
Luko K
Qureshi A
Baridi A
Menon S
Madhu B
Escriu C
Lyons S
Vowler SL
Zecchini VR
Shaw G
Hessenkemper W
Russell R
Mohammed H
Stefanos N
Lynch AG
Grigorenko E
D'Santos C
Taylor C
Lamb A
Sriranjan R
Yang J
Stark R
Dehm SM
Rennie PS
Carroll JS
Griffiths JR
Tavaré S
Mills IG
McEwan IJ
Baniahmad A
Tilley WD
Neal DE
Source :
Journal of the National Cancer Institute [J Natl Cancer Inst] 2015 Dec 11; Vol. 108 (5). Date of Electronic Publication: 2015 Dec 11 (Print Publication: 2016).
Publication Year :
2015

Abstract

Background: The androgen receptor (AR) is a major drug target in prostate cancer (PCa). We profiled the AR-regulated kinome to identify clinically relevant and druggable effectors of AR signaling.<br />Methods: Using genome-wide approaches, we interrogated all AR regulated kinases. Among these, choline kinase alpha (CHKA) expression was evaluated in benign (n = 195), prostatic intraepithelial neoplasia (PIN) (n = 153) and prostate cancer (PCa) lesions (n = 359). We interrogated how CHKA regulates AR signaling using biochemical assays and investigated androgen regulation of CHKA expression in men with PCa, both untreated (n = 20) and treated with an androgen biosynthesis inhibitor degarelix (n = 27). We studied the effect of CHKA inhibition on the PCa transcriptome using RNA sequencing and tested the effect of CHKA inhibition on cell growth, clonogenic survival and invasion. Tumor xenografts (n = 6 per group) were generated in mice using genetically engineered prostate cancer cells with inducible CHKA knockdown. Data were analyzed with χ(2) tests, Cox regression analysis, and Kaplan-Meier methods. All statistical tests were two-sided.<br />Results: CHKA expression was shown to be androgen regulated in cell lines, xenografts, and human tissue (log fold change from 6.75 to 6.59, P = .002) and was positively associated with tumor stage. CHKA binds directly to the ligand-binding domain (LBD) of AR, enhancing its stability. As such, CHKA is the first kinase identified as an AR chaperone. Inhibition of CHKA repressed the AR transcriptional program including pathways enriched for regulation of protein folding, decreased AR protein levels, and inhibited the growth of PCa cell lines, human PCa explants, and tumor xenografts.<br />Conclusions: CHKA can act as an AR chaperone, providing, to our knowledge, the first evidence for kinases as molecular chaperones, making CHKA both a marker of tumor progression and a potential therapeutic target for PCa.<br /> (© The Author 2015. Published by Oxford University Press.)

Details

Language :
English
ISSN :
1460-2105
Volume :
108
Issue :
5
Database :
MEDLINE
Journal :
Journal of the National Cancer Institute
Publication Type :
Academic Journal
Accession number :
26657335
Full Text :
https://doi.org/10.1093/jnci/djv371